“Cadila Healthcare Limited and its subsidiary Zydus Pharmaceuticals (USA) Inc have finalised an agreement with Kowa Company Ltd, Kowa Pharmaceuticals America Inc and Nissan Chemical Industries Ltd to settle all outstanding patent litigation related to Livalo (pitavastatin calcium) tablets,” said the company in a BSE filings yesterday.
Pitavastatin, a member of the blood cholesterol lowering medication class of statins, is indicated for hypercholesterolaemia (elevated cholesterol) and for the prevention of cardiovascular disease. Pitavastatin was discovered in Japan by Nissan Chemical Industries and developed further by Kowa Pharmaceuticals. The drug was approved for use in the US by the FDA in 2009 under the trade name Livalo.
Under the terms of the agreement, Kowa and Nissan have granted Zydus a license to market its generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances. Other terms of the settlement were not disclosed.
 "Tabletting machine; Image Courtesy: Siegfried")